The Agreement allows HAVN Life to export naturally derived psilocybin from its Jamaica facility and grows roster of supply partners in the U.S. market VANCOUVER, BC, Feb. 10, 2022 /CNW/ – HAVN Life Sciences Inc.(CSE: HAVN) (OTC: HAVLF) (FSE: 5NP)(the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential…


Previous articleTrauma and Vulnerability to Suggestion: Redefining How We Understand Consent
Next articlePT294 – Andrew Tatarsky, Ph.D. & Juliana Mulligan – Vital Psychedelic Conversations